274 related articles for article (PubMed ID: 31713476)
1. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Gupta A
Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
Chakravarti HN; Nag A
J Endocrinol Invest; 2021 Mar; 44(3):481-492. PubMed ID: 32594451
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
[TBL] [Abstract][Full Text] [Related]
5. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
Echtay A; Andari E; Atallah P; Moufarrege R; Nemr R
Ethn Dis; 2017 Jan; 27(1):45-54. PubMed ID: 28115821
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
[TBL] [Abstract][Full Text] [Related]
7. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
10. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy.
Kumar A; Prakash AS
J ASEAN Fed Endocr Soc; 2019; 34(1):87-91. PubMed ID: 33442141
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose.
Kasthuri S; Poongothai S; Anjana RM; Selvakumar J; Muthukumar S; Kayalvizhi S; Tariq S; Honey E; Gupta PK; Venkatesan U; Mohan V
Diabetes Technol Ther; 2021 Mar; 23(3):213-220. PubMed ID: 32916063
[No Abstract] [Full Text] [Related]
15. A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience.
Gupta A; Malhotra P; Jamwal V; Khalse M
J Assoc Physicians India; 2021 Jul; 69(7):11-12. PubMed ID: 34431269
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
17. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
20. Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus.
Baidya A
Curr Diabetes Rev; 2022; 18(9):e180122200322. PubMed ID: 35040415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
